Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 19, 2026
Subject: FDA approval of Lynavoy (linerixibat) and ongoing asset divestiture.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and a strategic transaction. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Strategic Developments
- Regulatory Approval: The US FDA approved Lynavoy (linerixibat), an ileal bile acid transporter (IBAT) inhibitor, for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC). This is the first medicine approved in the US for this indication.
- Asset Divestiture: GSK announced a license agreement (dated March 9, 2026) under which Alfasigma S.p.A. will acquire worldwide exclusive rights to develop, manufacture, and commercialize linerixibat. The transaction is ongoing and subject to customary conditions, including regulatory clearances (e.g., Hart-Scott-Rodino Act).
- Global Pipeline Status: Regulatory reviews for Lynavoy are underway in the EU, UK, Canada, and China. The drug holds Orphan Drug Designation in the US, EU, and Japan, and priority review in China.
Outlook, Risks, and Management Commentary
Management Commentary: GSK leadership highlighted that this approval addresses a significant unmet need for patients suffering from debilitating itch, marking the first liver medicine approval from their pipeline. The company emphasized its commitment to advancing its hepatology pipeline for conditions such as chronic hepatitis B and steatotic liver disease (SLD).
Clinical Data: Approval was based on the GLISTEN Phase III trial, which met primary and key secondary endpoints. The trial demonstrated significant, rapid (week two), and sustained (24 weeks) improvements in itch scores versus placebo. The most frequent adverse events were diarrhea (61%) and abdominal pain (18%), mostly mild to moderate.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ due to risks described in GSK's 2025 Annual Report on Form 20-F. The divestiture to Alfasigma is contingent upon regulatory approvals.
Investor Verification Checklist
- Confirm the final closing date and financial terms of the license agreement with Alfasigma S.p.A.
- Monitor the status of regulatory reviews in the EU, UK, Canada, and China for Lynavoy.
- Review the "Risk Factors" section of the 2025 Form 20-F for details on potential impacts of the divestiture and regulatory uncertainties.
- Verify the commercialization timeline for Lynavoy under Alfasigma's ownership.